USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Metimedi Pharmaceuticals Co., Ltd.

USPTO PatentsView assignee record - 8 granted patents across 5 technology areas, recorded in grant years 2020–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61K (Preparations FOR Medical, Dental OR Toiletry Purposes).

RSS updates for this company

The verdict

According to USPTO PatentsView, Metimedi ranks #32,488 of 49,997 tracked US assignees by granted-patent volume, with 8 patents across 5 technology areas.

#32,488
of 49,997 US assignees by volume
Top 49%
by Innovation Score (35.5/100)
14.8
avg claims per patent

USPTO PatentsView assignee plate

Corpus R32488 · Foreign Corporation #32,488 · 8 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · SPAN-YRS · BOOK-RICH

  • GRANTS-MICRO 8 grants
  • MID-PACK #32,488/49,997
  • PHOTO-FINISH Mesnac
  • CPC-NARROW A61K · 5 areas
  • INNOV-THIN 35.5/100
  • CLAIMS-RICH 14.8 claims/avg
  • TYPE-FRNCORP Foreign Corp
  • SPAN-YRS 2020–2024 · 5y
  • BOOK-RICH 9/10 fields

Nearest grant-volume peer: Mesnac Co., Ltd. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Innovation-score neighbourhood around Metimedi

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Metimedi's Innovation Score is 35.5/100 (top 49% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Where Metimedi's grants concentrate

Metimedi Pharmaceuticals Co., Ltd. is a focused PatentsView assignee: 5 CPC subclasses with 100% of grants classified under A61K (Preparations FOR Medical, Dental OR Toiletry Purposes). Peak complete grant year is 2020 (2 grants) versus a trough of 1 in 2021. By volume, Metimedi sits between Mesnac Co., Ltd. and Microelettrica Scientifica S.P.A..

Metimedi's three-year grant acceleration

Metimedi Pharmaceuticals Co., Ltd. shows 5 grants in 2022–2024 against only 3 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Who files at Metimedi's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Metimedi holds 8 patents at rank #32,432, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Metimedi

By rank, the assignees closest to #32,432 in granted patent volume.

Leaders in A61K (Preparations FOR Medical)

Other assignees with the most granted patents in Metimedi's primary technology class.

Metimedi's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

35 Top 49% higher than 51% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

0.511.522.5 20202021202220232024 2
USPTO utility patent grants by year · 2020–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2020–2019 baseline. Full figures in the table below.

View data table
Metimedi Pharmaceuticals Co., Ltd. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2020 2 25.0%
2021 1 12.5%
2022 2 25.0%
2023 1 12.5%
2024 2 25.0%

Where it ranks

Overall rank by patents

#32,488

of 49,997 tracked assignees

Innovation Score

35.5 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Metimedi Pharmaceuticals Co., Ltd.'s patent record in context - here's where to go next.

  • Metimedi Pharmaceuticals Co., Ltd.'s lead technology class is A61K (Preparations FOR Medical, Dental OR Toiletry Purposes), 100% of its portfolio - see every assignee active in that class. Explore A61K
  • Ranked #32,488 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Metimedi Pharmaceuticals Co., Ltd. against Mesnac Co., Ltd., an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 35.5/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.